ID   ATLA1_HUMAN             Reviewed;         558 AA.
AC   Q8WXF7; A6NND5; A8K2C0; G5E9T1; O95890; Q69YH7; Q96FK0;
DT   24-OCT-2003, integrated into UniProtKB/Swiss-Prot.
DT   01-MAR-2002, sequence version 1.
DT   28-JUN-2023, entry version 180.
DE   RecName: Full=Atlastin-1;
DE            EC=3.6.5.-;
DE   AltName: Full=Brain-specific GTP-binding protein;
DE   AltName: Full=GTP-binding protein 3;
DE            Short=GBP-3;
DE            Short=hGBP3;
DE   AltName: Full=Guanine nucleotide-binding protein 3;
DE   AltName: Full=Spastic paraplegia 3 protein A;
GN   Name=ATL1; Synonyms=GBP3, SPG3A;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS SPG3 CYS-239; ARG-258
RP   AND TYR-259.
RX   PubMed=11685207; DOI=10.1038/ng758;
RA   Zhao X., Alvarado D., Rainier S., Lemons R., Hedera P., Weber C.H.,
RA   Tukel T., Apak M., Heiman-Patterson T., Ming L., Bui M., Fink J.K.;
RT   "Mutations in a newly identified GTPase gene cause autosomal dominant
RT   hereditary spastic paraplegia.";
RL   Nat. Genet. 29:326-331(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND INTERACTION WITH MAP4K4.
RX   PubMed=12387898; DOI=10.1016/s0014-5793(02)03467-1;
RA   Luan Z., Zhang Y., Liu A., Man Y., Cheng L., Hu G.;
RT   "A novel GTP-binding protein hGBP3 interacts with NIK/HGK.";
RL   FEBS Lett. 530:233-238(2002).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Thalamus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Endometrium;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12508121; DOI=10.1038/nature01348;
RA   Heilig R., Eckenberg R., Petit J.-L., Fonknechten N., Da Silva C.,
RA   Cattolico L., Levy M., Barbe V., De Berardinis V., Ureta-Vidal A.,
RA   Pelletier E., Vico V., Anthouard V., Rowen L., Madan A., Qin S., Sun H.,
RA   Du H., Pepin K., Artiguenave F., Robert C., Cruaud C., Bruels T.,
RA   Jaillon O., Friedlander L., Samson G., Brottier P., Cure S., Segurens B.,
RA   Aniere F., Samain S., Crespeau H., Abbasi N., Aiach N., Boscus D.,
RA   Dickhoff R., Dors M., Dubois I., Friedman C., Gouyvenoux M., James R.,
RA   Madan A., Mairey-Estrada B., Mangenot S., Martins N., Menard M., Oztas S.,
RA   Ratcliffe A., Shaffer T., Trask B., Vacherie B., Bellemere C., Belser C.,
RA   Besnard-Gonnet M., Bartol-Mavel D., Boutard M., Briez-Silla S.,
RA   Combette S., Dufosse-Laurent V., Ferron C., Lechaplais C., Louesse C.,
RA   Muselet D., Magdelenat G., Pateau E., Petit E., Sirvain-Trukniewicz P.,
RA   Trybou A., Vega-Czarny N., Bataille E., Bluet E., Bordelais I., Dubois M.,
RA   Dumont C., Guerin T., Haffray S., Hammadi R., Muanga J., Pellouin V.,
RA   Robert D., Wunderle E., Gauguet G., Roy A., Sainte-Marthe L., Verdier J.,
RA   Verdier-Discala C., Hillier L.W., Fulton L., McPherson J., Matsuda F.,
RA   Wilson R., Scarpelli C., Gyapay G., Wincker P., Saurin W., Quetier F.,
RA   Waterston R., Hood L., Weissenbach J.;
RT   "The DNA sequence and analysis of human chromosome 14.";
RL   Nature 421:601-607(2003).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANTS GLU-43 AND
RP   CYS-193.
RC   TISSUE=Eye;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 80-558 (ISOFORM 1).
RC   TISSUE=Brain;
RA   Mei G., Yu W., Gibbs R.A.;
RL   Submitted (FEB-1999) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   FUNCTION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, REGION, TOPOLOGY, AND
RP   SUBUNIT.
RX   PubMed=14506257; DOI=10.1074/jbc.m306702200;
RA   Zhu P.-P., Patterson A., Lavoie B., Stadler J., Shoeb M., Patel R.,
RA   Blackstone C.;
RT   "Cellular localization, oligomerization, and membrane association of the
RT   hereditary spastic paraplegia 3A (SPG3A) protein atlastin.";
RL   J. Biol. Chem. 278:49063-49071(2003).
RN   [10]
RP   INTERACTION WITH SPAST, AND SUBCELLULAR LOCATION.
RX   PubMed=16339213; DOI=10.1093/hmg/ddi447;
RA   Sanderson C.M., Connell J.W., Edwards T.L., Bright N.A., Duley S.,
RA   Thompson A., Luzio J.P., Reid E.;
RT   "Spastin and atlastin, two proteins mutated in autosomal-dominant
RT   hereditary spastic paraplegia, are binding partners.";
RL   Hum. Mol. Genet. 15:307-318(2006).
RN   [11]
RP   INTERACTION WITH SPAST.
RX   PubMed=16815977; DOI=10.1073/pnas.0510863103;
RA   Evans K.J., Keller C., Pavur K., Glasgow K., Conn B., Lauring B.P.;
RT   "Interaction of two hereditary spastic paraplegia gene products, spastin
RT   and atlastin, suggests a common pathway for axonal maintenance.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:10666-10671(2006).
RN   [12]
RP   FUNCTION, SUBCELLULAR LOCATION, CHARACTERIZATION OF VARIANTS SPG3 PRO-161;
RP   CYS-239 AND TRP-495, MUTAGENESIS OF PHE-151; THR-162 AND SER-398,
RP   INTERACTION WITH TMED2, AND TISSUE SPECIFICITY.
RX   PubMed=17321752; DOI=10.1016/j.mcn.2007.01.012;
RA   Namekawa M., Muriel M.-P., Janer A., Latouche M., Dauphin A., Debeir T.,
RA   Martin E., Duyckaerts C., Prigent A., Depienne C., Sittler A., Brice A.,
RA   Ruberg M.;
RT   "Mutations in the SPG3A gene encoding the GTPase atlastin interfere with
RT   vesicle trafficking in the ER/Golgi interface and Golgi morphogenesis.";
RL   Mol. Cell. Neurosci. 35:1-13(2007).
RN   [13]
RP   FUNCTION, CHARACTERIZATION OF VARIANT SPAG3 GLN-217, MUTAGENESIS OF LYS-80,
RP   AND TISSUE SPECIFICITY.
RX   PubMed=18270207; DOI=10.1093/hmg/ddn046;
RA   Rismanchi N., Soderblom C., Stadler J., Zhu P.-P., Blackstone C.;
RT   "Atlastin GTPases are required for Golgi apparatus and ER morphogenesis.";
RL   Hum. Mol. Genet. 17:1591-1604(2008).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Platelet;
RX   PubMed=18088087; DOI=10.1021/pr0704130;
RA   Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA   Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT   "Phosphoproteome of resting human platelets.";
RL   J. Proteome Res. 7:526-534(2008).
RN   [15]
RP   FUNCTION, INTERACTION WITH REEP5; RTN3 AND RTN4, AND SUBCELLULAR LOCATION.
RX   PubMed=19665976; DOI=10.1016/j.cell.2009.05.025;
RA   Hu J., Shibata Y., Zhu P.-P., Voss C., Rismanchi N., Prinz W.A.,
RA   Rapoport T.A., Blackstone C.;
RT   "A class of dynamin-like GTPases involved in the generation of the tubular
RT   ER network.";
RL   Cell 138:549-561(2009).
RN   [16]
RP   INTERACTION WITH REEP1.
RX   PubMed=20200447; DOI=10.1172/jci40979;
RA   Park S.H., Zhu P.P., Parker R.L., Blackstone C.;
RT   "Hereditary spastic paraplegia proteins REEP1, spastin, and atlastin-1
RT   coordinate microtubule interactions with the tubular ER network.";
RL   J. Clin. Invest. 120:1097-1110(2010).
RN   [17]
RP   INTERACTION WITH ZFYVE27.
RX   PubMed=23969831; DOI=10.1073/pnas.1307391110;
RA   Chang J., Lee S., Blackstone C.;
RT   "Protrudin binds atlastins and endoplasmic reticulum-shaping proteins and
RT   regulates network formation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 110:14954-14959(2013).
RN   [18]
RP   INTERACTION WITH CPT1C.
RX   PubMed=25751282; DOI=10.1001/jamaneurol.2014.4769;
RA   Rinaldi C., Schmidt T., Situ A.J., Johnson J.O., Lee P.R., Chen K.L.,
RA   Bott L.C., Fado R., Harmison G.H., Parodi S., Grunseich C., Renvoise B.,
RA   Biesecker L.G., De Michele G., Santorelli F.M., Filla A., Stevanin G.,
RA   Duerr A., Brice A., Casals N., Traynor B.J., Blackstone C., Ulmer T.S.,
RA   Fischbeck K.H.;
RT   "Mutation in CPT1C Associated with pure autosomal dominant spastic
RT   paraplegia.";
RL   JAMA Neurol. 72:561-570(2015).
RN   [19]
RP   FUNCTION, SUBCELLULAR LOCATION, CHARACTERIZATION OF VARIANT GLN-217, AND
RP   MUTAGENESIS OF LYS-80.
RX   PubMed=27619977; DOI=10.7554/elife.18605;
RA   Wang S., Tukachinsky H., Romano F.B., Rapoport T.A.;
RT   "Cooperation of the ER-shaping proteins atlastin, lunapark, and reticulons
RT   to generate a tubular membrane network.";
RL   Elife 5:0-0(2016).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (2.70 ANGSTROMS) OF 1-447 IN COMPLEX WITH GDP,
RP   FUNCTION, CHARACTERIZATION OF VARIANT CYS-196, CHARACTERIZATION OF VARIANT
RP   SPAG3 GLN-217, MUTAGENESIS OF ARG-77; GLN-191 AND HIS-247, AND SUBUNIT.
RX   PubMed=21220294; DOI=10.1073/pnas.1012792108;
RA   Byrnes L.J., Sondermann H.;
RT   "Structural basis for the nucleotide-dependent dimerization of the large G
RT   protein atlastin-1/SPG3A.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:2216-2221(2011).
RN   [21]
RP   X-RAY CRYSTALLOGRAPHY (2.80 ANGSTROMS) OF 18-447IN COMPLEX WITH GDP, AND
RP   SUBUNIT.
RX   PubMed=21368113; DOI=10.1073/pnas.1101643108;
RA   Bian X., Klemm R.W., Liu T.Y., Zhang M., Sun S., Sui X., Liu X.,
RA   Rapoport T.A., Hu J.;
RT   "Structures of the atlastin GTPase provide insight into homotypic fusion of
RT   endoplasmic reticulum membranes.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:3976-3981(2011).
RN   [22]
RP   X-RAY CRYSTALLOGRAPHY (2.09 ANGSTROMS) OF 1-446 IN COMPLEX WITH GTP ANALOG,
RP   FUNCTION, SUBUNIT, AND MUTAGENESIS OF ARG-77.
RX   PubMed=23334294; DOI=10.1038/emboj.2012.353;
RA   Byrnes L.J., Singh A., Szeto K., Benvin N.M., O'Donnell J.P., Zipfel W.R.,
RA   Sondermann H.;
RT   "Structural basis for conformational switching and GTP loading of the large
RT   G protein atlastin.";
RL   EMBO J. 32:369-384(2013).
RN   [23]
RP   VARIANT SPG3 GLN-217.
RX   PubMed=12112092; DOI=10.1002/ana.10185;
RA   Muglia M., Magariello A., Nicoletti G., Patitucci A., Gabriele A.L.,
RA   Conforti F.L., Mazzei R., Caracciolo M., Ardito B., Lastilla M.,
RA   Tedeschi G., Quattrone A.;
RT   "Further evidence that SPG3A gene mutations cause autosomal dominant
RT   hereditary spastic paraplegia.";
RL   Ann. Neurol. 51:794-795(2002).
RN   [24]
RP   VARIANT SPG3 VAL-408.
RX   PubMed=12939451; DOI=10.1212/01.wnl.0000078189.73611.df;
RA   Dalpozzo F., Rossetto M.G., Boaretto F., Sartori E., Mostacciuolo M.L.,
RA   Daga A., Bassi M.T., Martinuzzi A.;
RT   "Infancy onset hereditary spastic paraplegia associated with a novel
RT   atlastin mutation.";
RL   Neurology 61:580-581(2003).
RN   [25]
RP   VARIANTS SPG3 PRO-161 AND PRO-247.
RX   PubMed=14695538; DOI=10.1002/humu.9205;
RA   Sauter S.M., Engel W., Neumann L.M., Kunze J., Neesen J.;
RT   "Novel mutations in the Atlastin gene (SPG3A) in families with autosomal
RT   dominant hereditary spastic paraplegia and evidence for late onset forms of
RT   HSP linked to the SPG3A locus.";
RL   Hum. Mutat. 23:98-98(2004).
RN   [26]
RP   VARIANT SPG3 TRP-415.
RX   PubMed=15184642; DOI=10.1212/01.wnl.0000127698.88895.85;
RA   D'Amico A., Tessa A., Sabino A., Bertini E., Santorelli F.M., Servidei S.;
RT   "Incomplete penetrance in an SPG3A-linked family with a new mutation in the
RT   atlastin gene.";
RL   Neurology 62:2138-2139(2004).
RN   [27]
RP   VARIANT SPG3 TRP-157.
RX   PubMed=16533974; DOI=10.1001/archneur.63.3.445;
RA   Rainier S., Sher C., Reish O., Thomas D., Fink J.K.;
RT   "De novo occurrence of novel SPG3A/atlastin mutation presenting as cerebral
RT   palsy.";
RL   Arch. Neurol. 63:445-447(2006).
RN   [28]
RP   VARIANT SPG3 ASN-436 DEL, AND CHARACTERIZATION OF VARIANT SPG3 ASN-436 DEL.
RX   PubMed=17427918; DOI=10.1002/ana.21114;
RA   Meijer I.A., Dion P., Laurent S., Dupre N., Brais B., Levert A.,
RA   Puymirat J., Rioux M.F., Sylvain M., Zhu P.P., Soderblom C., Stadler J.,
RA   Blackstone C., Rouleau G.A.;
RT   "Characterization of a novel SPG3A deletion in a French-Canadian family.";
RL   Ann. Neurol. 61:599-603(2007).
RN   [29]
RP   VARIANTS SPG3 GLU-154; CYS-239; ILE-253; VAL-413; TRP-415; THR-440 AND
RP   TRP-495.
RX   PubMed=20932283; DOI=10.1186/1471-2377-10-89;
RA   Alvarez V., Sanchez-Ferrero E., Beetz C., Diaz M., Alonso B., Corao A.I.,
RA   Gamez J., Esteban J., Gonzalo J.F., Pascual-Pascual S.I.,
RA   Lopez de Munain A., Moris G., Ribacoba R., Marquez C., Rosell J., Marin R.,
RA   Garcia-Barcina M.J., Del Castillo E., Benito C., Coto E.;
RT   "Mutational spectrum of the SPG4 (SPAST) and SPG3A (ATL1) genes in Spanish
RT   patients with hereditary spastic paraplegia.";
RL   BMC Neurol. 10:89-89(2010).
RN   [30]
RP   VARIANTS HSN1D GLN-66 AND LYS-355, AND CHARACTERIZATION OF VARIANTS HSN1D
RP   GLN-66 AND LYS-355.
RX   PubMed=21194679; DOI=10.1016/j.ajhg.2010.12.003;
RA   Guelly C., Zhu P.P., Leonardis L., Papic L., Zidar J., Schabhuttl M.,
RA   Strohmaier H., Weis J., Strom T.M., Baets J., Willems J., De Jonghe P.,
RA   Reilly M.M., Frohlich E., Hatz M., Trajanoski S., Pieber T.R.,
RA   Janecke A.R., Blackstone C., Auer-Grumbach M.;
RT   "Targeted high-throughput sequencing identifies mutations in atlastin-1 as
RT   a cause of hereditary sensory neuropathy type I.";
RL   Am. J. Hum. Genet. 88:99-105(2011).
RN   [31]
RP   VARIANT CYS-196, AND VARIANTS SPG3 CYS-239; ILE-253 AND TRP-495.
RX   PubMed=20718791; DOI=10.1111/j.1399-0004.2010.01501.x;
RA   McCorquodale D.S. III, Ozomaro U., Huang J., Montenegro G., Kushman A.,
RA   Citrigno L., Price J., Speziani F., Pericak-Vance M.A., Zuchner S.;
RT   "Mutation screening of spastin, atlastin, and REEP1 in hereditary spastic
RT   paraplegia.";
RL   Clin. Genet. 79:523-530(2011).
RN   [32]
RP   VARIANT SPG3 CYS-416.
RX   PubMed=21336785; DOI=10.1007/s00415-011-5934-z;
RA   Orlacchio A., Montieri P., Babalini C., Gaudiello F., Bernardi G.,
RA   Kawarai T.;
RT   "Late-onset hereditary spastic paraplegia with thin corpus callosum caused
RT   by a new SPG3A mutation.";
RL   J. Neurol. 258:1361-1363(2011).
RN   [33]
RP   VARIANTS SPG3 GLN-415 AND TRP-415.
RX   PubMed=23483706; DOI=10.1002/humu.22309;
RA   Varga R.E., Schuele R., Fadel H., Valenzuela I., Speziani F., Gonzalez M.,
RA   Rudenskaia G., Nuernberg G., Thiele H., Altmueller J., Alvarez V.,
RA   Gamez J., Garbern J.Y., Nuernberg P., Zuchner S., Beetz C.;
RT   "Do not trust the pedigree: reduced and sex-dependent penetrance at a novel
RT   mutation hotspot in ATL1 blurs autosomal dominant inheritance of spastic
RT   paraplegia.";
RL   Hum. Mutat. 34:860-863(2013).
RN   [34]
RP   VARIANT SPG3 GLN-118.
RX   PubMed=24473461; DOI=10.1038/ejhg.2014.5;
RA   Khan T.N., Klar J., Tariq M., Anjum Baig S., Malik N.A., Yousaf R.,
RA   Baig S.M., Dahl N.;
RT   "Evidence for autosomal recessive inheritance in SPG3A caused by
RT   homozygosity for a novel ATL1 missense mutation.";
RL   Eur. J. Hum. Genet. 22:1180-1184(2014).
RN   [35]
RP   VARIANT SPG3 ILE-253.
RX   PubMed=24604904; DOI=10.1136/jnnp-2013-306740;
RA   Klein C.J., Middha S., Duan X., Wu Y., Litchy W.J., Gu W., Dyck P.J.,
RA   Gavrilova R.H., Smith D.I., Kocher J.P., Dyck P.J.;
RT   "Application of whole exome sequencing in undiagnosed inherited
RT   polyneuropathies.";
RL   J. Neurol. Neurosurg. Psych. 85:1265-1272(2014).
CC   -!- FUNCTION: GTPase tethering membranes through formation of trans-
CC       homooligomers and mediating homotypic fusion of endoplasmic reticulum
CC       membranes. Functions in endoplasmic reticulum tubular network
CC       biogenesis (PubMed:27619977). May also regulate Golgi biogenesis. May
CC       regulate axonal development. {ECO:0000269|PubMed:14506257,
CC       ECO:0000269|PubMed:17321752, ECO:0000269|PubMed:18270207,
CC       ECO:0000269|PubMed:19665976, ECO:0000269|PubMed:21220294,
CC       ECO:0000269|PubMed:23334294, ECO:0000269|PubMed:25751282,
CC       ECO:0000269|PubMed:27619977}.
CC   -!- SUBUNIT: Monomer as apoprotein and in the GDP-bound form. Homodimer in
CC       the GTP-bound form. Interacts (via N-terminal region) with MAP4K4 (via
CC       CNH regulatory domain). Interacts with REEP5, RTN3 and RTN4 (via the
CC       transmembrane region). Interacts with SPAST; interaction is direct. May
CC       interact with TMED2. Interacts with REEP1. Interacts with CPT1C.
CC       Interacts with ARL6IP1 (By similarity). Interacts with ZFYVE27
CC       (PubMed:23969831). {ECO:0000250|UniProtKB:Q6PST4,
CC       ECO:0000250|UniProtKB:Q8BH66, ECO:0000269|PubMed:12387898,
CC       ECO:0000269|PubMed:14506257, ECO:0000269|PubMed:16339213,
CC       ECO:0000269|PubMed:16815977, ECO:0000269|PubMed:17321752,
CC       ECO:0000269|PubMed:19665976, ECO:0000269|PubMed:20200447,
CC       ECO:0000269|PubMed:21220294, ECO:0000269|PubMed:21368113,
CC       ECO:0000269|PubMed:23334294, ECO:0000269|PubMed:23969831}.
CC   -!- INTERACTION:
CC       Q8WXF7; Q8WXF7: ATL1; NbExp=13; IntAct=EBI-2410266, EBI-2410266;
CC       Q8WXF7; Q8N5K1: CISD2; NbExp=3; IntAct=EBI-2410266, EBI-1045797;
CC       Q8WXF7; P50570-2: DNM2; NbExp=3; IntAct=EBI-2410266, EBI-10968534;
CC       Q8WXF7; P42858: HTT; NbExp=18; IntAct=EBI-2410266, EBI-466029;
CC       Q8WXF7; Q8WXH2: JPH3; NbExp=3; IntAct=EBI-2410266, EBI-1055254;
CC       Q8WXF7; P02545: LMNA; NbExp=3; IntAct=EBI-2410266, EBI-351935;
CC       Q8WXF7; P19404: NDUFV2; NbExp=3; IntAct=EBI-2410266, EBI-713665;
CC       Q8WXF7; P35240: NF2; NbExp=3; IntAct=EBI-2410266, EBI-1014472;
CC       Q8WXF7; Q96CV9: OPTN; NbExp=3; IntAct=EBI-2410266, EBI-748974;
CC       Q8WXF7; Q9BZ23-2: PANK2; NbExp=3; IntAct=EBI-2410266, EBI-25929070;
CC       Q8WXF7; O00628-2: PEX7; NbExp=3; IntAct=EBI-2410266, EBI-25882083;
CC       Q8WXF7; P50897: PPT1; NbExp=3; IntAct=EBI-2410266, EBI-1237011;
CC       Q8WXF7; P04156: PRNP; NbExp=3; IntAct=EBI-2410266, EBI-977302;
CC       Q8WXF7; P41219: PRPH; NbExp=3; IntAct=EBI-2410266, EBI-752074;
CC       Q8WXF7; P51149: RAB7A; NbExp=3; IntAct=EBI-2410266, EBI-1056089;
CC       Q8WXF7; Q9NQC3-1: RTN4; NbExp=2; IntAct=EBI-2410266, EBI-715972;
CC       Q8WXF7; Q16637: SMN2; NbExp=3; IntAct=EBI-2410266, EBI-395421;
CC       Q8WXF7; Q7Z699: SPRED1; NbExp=3; IntAct=EBI-2410266, EBI-5235340;
CC       Q8WXF7; Q86WV8: TSC1; NbExp=3; IntAct=EBI-2410266, EBI-12806590;
CC       Q8WXF7; P54577: YARS1; NbExp=3; IntAct=EBI-2410266, EBI-1048893;
CC       Q8WXF7; Q5T4F4: ZFYVE27; NbExp=6; IntAct=EBI-2410266, EBI-3892947;
CC       Q8WXF7; Q60870: Reep5; Xeno; NbExp=2; IntAct=EBI-2410266, EBI-2410304;
CC       Q8WXF7; Q9ES97-3: Rtn3; Xeno; NbExp=3; IntAct=EBI-2410266, EBI-1487798;
CC       Q8WXF7; Q9JK11-3: Rtn4; Xeno; NbExp=2; IntAct=EBI-2410266, EBI-920002;
CC       Q8WXF7-1; Q8WXF7-1: ATL1; NbExp=4; IntAct=EBI-15590227, EBI-15590227;
CC       Q8WXF7-1; Q9UBP0: SPAST; NbExp=4; IntAct=EBI-15590227, EBI-1222832;
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane
CC       {ECO:0000269|PubMed:14506257, ECO:0000269|PubMed:16339213,
CC       ECO:0000269|PubMed:17321752, ECO:0000269|PubMed:19665976,
CC       ECO:0000269|PubMed:27619977}; Multi-pass membrane protein
CC       {ECO:0000269|PubMed:14506257, ECO:0000269|PubMed:16339213,
CC       ECO:0000269|PubMed:17321752, ECO:0000269|PubMed:19665976}. Golgi
CC       apparatus membrane {ECO:0000269|PubMed:14506257,
CC       ECO:0000269|PubMed:17321752}; Multi-pass membrane protein
CC       {ECO:0000269|PubMed:14506257, ECO:0000269|PubMed:17321752}. Cell
CC       projection, axon {ECO:0000250|UniProtKB:Q6PST4}. Note=Localizes to
CC       endoplasmic reticulum tubular network (PubMed:27619977).
CC       {ECO:0000269|PubMed:27619977}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q8WXF7-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q8WXF7-2; Sequence=VSP_044864;
CC   -!- TISSUE SPECIFICITY: Expressed predominantly in the adult and fetal
CC       central nervous system. Measurable expression in all tissues examined,
CC       although expression in adult brain is at least 50-fold higher than in
CC       other tissues. Detected predominantly in pyramidal neurons in the
CC       cerebral cortex and the hippocampus of the brain. Expressed in upper
CC       and lower motor neurons (at protein level).
CC       {ECO:0000269|PubMed:14506257, ECO:0000269|PubMed:17321752,
CC       ECO:0000269|PubMed:18270207}.
CC   -!- DISEASE: Spastic paraplegia 3, autosomal dominant (SPG3) [MIM:182600]:
CC       A form of spastic paraplegia, a neurodegenerative disorder
CC       characterized by a slow, gradual, progressive weakness and spasticity
CC       of the lower limbs. Rate of progression and the severity of symptoms
CC       are quite variable. Initial symptoms may include difficulty with
CC       balance, weakness and stiffness in the legs, muscle spasms, and
CC       dragging the toes when walking. In some forms of the disorder, bladder
CC       symptoms (such as incontinence) may appear, or the weakness and
CC       stiffness may spread to other parts of the body.
CC       {ECO:0000269|PubMed:11685207, ECO:0000269|PubMed:12112092,
CC       ECO:0000269|PubMed:12939451, ECO:0000269|PubMed:14695538,
CC       ECO:0000269|PubMed:15184642, ECO:0000269|PubMed:16533974,
CC       ECO:0000269|PubMed:17321752, ECO:0000269|PubMed:17427918,
CC       ECO:0000269|PubMed:20718791, ECO:0000269|PubMed:20932283,
CC       ECO:0000269|PubMed:21336785, ECO:0000269|PubMed:23483706,
CC       ECO:0000269|PubMed:24473461, ECO:0000269|PubMed:24604904}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Neuropathy, hereditary sensory, 1D (HSN1D) [MIM:613708]: A
CC       disease characterized by adult-onset distal axonal sensory neuropathy
CC       leading to mutilating ulcerations as well as hyporeflexia. Some
CC       patients may show features suggesting upper neuron involvement.
CC       {ECO:0000269|PubMed:21194679}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the TRAFAC class dynamin-like GTPase
CC       superfamily. GB1/RHD3 GTPase family. GB1 subfamily.
CC       {ECO:0000255|PROSITE-ProRule:PRU01052}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAD20047.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC       Sequence=AAK51160.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AY032844; AAK51160.1; ALT_INIT; mRNA.
DR   EMBL; AF444143; AAL37898.1; -; mRNA.
DR   EMBL; AK290185; BAF82874.1; -; mRNA.
DR   EMBL; AL833591; CAH10392.1; -; mRNA.
DR   EMBL; AL118556; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL606834; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471078; EAW65705.1; -; Genomic_DNA.
DR   EMBL; CH471078; EAW65706.1; -; Genomic_DNA.
DR   EMBL; BC010708; AAH10708.2; -; mRNA.
DR   EMBL; AF131801; AAD20047.1; ALT_INIT; mRNA.
DR   CCDS; CCDS32077.1; -. [Q8WXF7-2]
DR   CCDS; CCDS9700.1; -. [Q8WXF7-1]
DR   RefSeq; NP_001121185.1; NM_001127713.1. [Q8WXF7-2]
DR   RefSeq; NP_056999.2; NM_015915.4. [Q8WXF7-1]
DR   RefSeq; NP_853629.2; NM_181598.3. [Q8WXF7-2]
DR   PDB; 3Q5D; X-ray; 2.70 A; A=1-447.
DR   PDB; 3Q5E; X-ray; 3.01 A; A/C/E/G=1-447.
DR   PDB; 3QNU; X-ray; 2.80 A; A=18-447.
DR   PDB; 3QOF; X-ray; 2.80 A; A/B/C/D=18-447.
DR   PDB; 4IDN; X-ray; 2.25 A; A/B=1-446.
DR   PDB; 4IDO; X-ray; 2.09 A; A/B=1-446.
DR   PDB; 4IDP; X-ray; 2.59 A; A/B/C/D=1-446.
DR   PDB; 4IDQ; X-ray; 2.30 A; A/B/C/D=1-446.
DR   PDB; 6B9D; X-ray; 1.95 A; A/B=1-446.
DR   PDB; 6B9E; X-ray; 1.99 A; A/B=1-446.
DR   PDB; 6B9F; X-ray; 1.90 A; A/B=1-446.
DR   PDB; 6B9G; X-ray; 3.00 A; A/B/C/D=1-339.
DR   PDB; 6XJN; X-ray; 2.20 A; A=1-439.
DR   PDB; 7OL3; X-ray; 1.90 A; A/B=1-449.
DR   PDBsum; 3Q5D; -.
DR   PDBsum; 3Q5E; -.
DR   PDBsum; 3QNU; -.
DR   PDBsum; 3QOF; -.
DR   PDBsum; 4IDN; -.
DR   PDBsum; 4IDO; -.
DR   PDBsum; 4IDP; -.
DR   PDBsum; 4IDQ; -.
DR   PDBsum; 6B9D; -.
DR   PDBsum; 6B9E; -.
DR   PDBsum; 6B9F; -.
DR   PDBsum; 6B9G; -.
DR   PDBsum; 6XJN; -.
DR   PDBsum; 7OL3; -.
DR   AlphaFoldDB; Q8WXF7; -.
DR   SMR; Q8WXF7; -.
DR   BioGRID; 119254; 55.
DR   CORUM; Q8WXF7; -.
DR   DIP; DIP-53502N; -.
DR   IntAct; Q8WXF7; 31.
DR   MINT; Q8WXF7; -.
DR   STRING; 9606.ENSP00000351155; -.
DR   TCDB; 1.N.5.1.1; the endoplasmic reticulum fusion gtpase, atlastin (atlastin) family.
DR   iPTMnet; Q8WXF7; -.
DR   PhosphoSitePlus; Q8WXF7; -.
DR   SwissPalm; Q8WXF7; -.
DR   BioMuta; ATL1; -.
DR   DMDM; 37999727; -.
DR   EPD; Q8WXF7; -.
DR   jPOST; Q8WXF7; -.
DR   MassIVE; Q8WXF7; -.
DR   MaxQB; Q8WXF7; -.
DR   PaxDb; Q8WXF7; -.
DR   PeptideAtlas; Q8WXF7; -.
DR   ProteomicsDB; 34035; -.
DR   ProteomicsDB; 75028; -. [Q8WXF7-1]
DR   Antibodypedia; 23673; 264 antibodies from 29 providers.
DR   DNASU; 51062; -.
DR   Ensembl; ENST00000358385.12; ENSP00000351155.7; ENSG00000198513.14. [Q8WXF7-1]
DR   Ensembl; ENST00000441560.6; ENSP00000413675.2; ENSG00000198513.14. [Q8WXF7-2]
DR   Ensembl; ENST00000553509.2; ENSP00000450989.2; ENSG00000198513.14. [Q8WXF7-2]
DR   Ensembl; ENST00000556478.3; ENSP00000501428.2; ENSG00000198513.14. [Q8WXF7-2]
DR   GeneID; 51062; -.
DR   KEGG; hsa:51062; -.
DR   MANE-Select; ENST00000358385.12; ENSP00000351155.7; NM_015915.5; NP_056999.2.
DR   UCSC; uc001wyd.5; human. [Q8WXF7-1]
DR   AGR; HGNC:11231; -.
DR   CTD; 51062; -.
DR   DisGeNET; 51062; -.
DR   GeneCards; ATL1; -.
DR   GeneReviews; ATL1; -.
DR   HGNC; HGNC:11231; ATL1.
DR   HPA; ENSG00000198513; Tissue enhanced (brain).
DR   MalaCards; ATL1; -.
DR   MIM; 182600; phenotype.
DR   MIM; 606439; gene.
DR   MIM; 613708; phenotype.
DR   neXtProt; NX_Q8WXF7; -.
DR   OpenTargets; ENSG00000198513; -.
DR   Orphanet; 100984; Autosomal dominant spastic paraplegia type 3.
DR   Orphanet; 36386; Hereditary sensory and autonomic neuropathy type 1.
DR   PharmGKB; PA36061; -.
DR   VEuPathDB; HostDB:ENSG00000198513; -.
DR   eggNOG; KOG2037; Eukaryota.
DR   GeneTree; ENSGT00940000158704; -.
DR   HOGENOM; CLU_021447_2_0_1; -.
DR   InParanoid; Q8WXF7; -.
DR   OMA; YMAIYKG; -.
DR   OrthoDB; 102682at2759; -.
DR   PhylomeDB; Q8WXF7; -.
DR   TreeFam; TF105251; -.
DR   PathwayCommons; Q8WXF7; -.
DR   SignaLink; Q8WXF7; -.
DR   BioGRID-ORCS; 51062; 29 hits in 1151 CRISPR screens.
DR   ChiTaRS; ATL1; human.
DR   EvolutionaryTrace; Q8WXF7; -.
DR   GeneWiki; Atlastin; -.
DR   GenomeRNAi; 51062; -.
DR   Pharos; Q8WXF7; Tbio.
DR   PRO; PR:Q8WXF7; -.
DR   Proteomes; UP000005640; Chromosome 14.
DR   RNAct; Q8WXF7; protein.
DR   Bgee; ENSG00000198513; Expressed in middle temporal gyrus and 170 other tissues.
DR   ExpressionAtlas; Q8WXF7; baseline and differential.
DR   Genevisible; Q8WXF7; HS.
DR   GO; GO:0030424; C:axon; IEA:UniProtKB-SubCell.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:UniProtKB.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; ISS:UniProtKB.
DR   GO; GO:0071782; C:endoplasmic reticulum tubular network; ISS:UniProtKB.
DR   GO; GO:0098826; C:endoplasmic reticulum tubular network membrane; IDA:UniProtKB.
DR   GO; GO:0005794; C:Golgi apparatus; ISS:UniProtKB.
DR   GO; GO:0000137; C:Golgi cis cisterna; ISS:UniProtKB.
DR   GO; GO:0000139; C:Golgi membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0005525; F:GTP binding; ISS:UniProtKB.
DR   GO; GO:0003924; F:GTPase activity; IDA:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IDA:UniProtKB.
DR   GO; GO:0007409; P:axonogenesis; ISS:UniProtKB.
DR   GO; GO:0007029; P:endoplasmic reticulum organization; IDA:UniProtKB.
DR   GO; GO:1990809; P:endoplasmic reticulum tubular network membrane organization; IMP:UniProtKB.
DR   GO; GO:0051260; P:protein homooligomerization; IDA:UniProtKB.
DR   CDD; cd01851; GBP; 1.
DR   Gene3D; 1.20.58.420; AHSP; 1.
DR   Gene3D; 3.40.50.300; P-loop containing nucleotide triphosphate hydrolases; 1.
DR   InterPro; IPR030386; G_GB1_RHD3_dom.
DR   InterPro; IPR036543; Guanylate-bd_C_sf.
DR   InterPro; IPR015894; Guanylate-bd_N.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   PANTHER; PTHR10751:SF15; ATLASTIN-1; 1.
DR   PANTHER; PTHR10751; GUANYLATE BINDING PROTEIN; 1.
DR   Pfam; PF02263; GBP; 1.
DR   SUPFAM; SSF48340; Interferon-induced guanylate-binding protein 1 (GBP1), C-terminal domain; 1.
DR   SUPFAM; SSF52540; P-loop containing nucleoside triphosphate hydrolases; 1.
DR   PROSITE; PS51715; G_GB1_RHD3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Cell projection;
KW   Coiled coil; Disease variant; Endoplasmic reticulum; Golgi apparatus;
KW   GTP-binding; Hereditary spastic paraplegia; Hydrolase; Membrane;
KW   Neurodegeneration; Neuropathy; Nucleotide-binding; Phosphoprotein;
KW   Reference proteome; Transmembrane; Transmembrane helix.
FT   CHAIN           1..558
FT                   /note="Atlastin-1"
FT                   /id="PRO_0000190971"
FT   TOPO_DOM        1..449
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:14506257"
FT   TRANSMEM        450..470
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        471
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        472..492
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        493..558
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:14506257"
FT   DOMAIN          64..309
FT                   /note="GB1/RHD3-type G"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01052"
FT   REGION          1..27
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          448..558
FT                   /note="Sufficient for membrane association"
FT   COILED          412..439
FT                   /evidence="ECO:0000255"
FT   BINDING         74..81
FT                   /ligand="GTP"
FT                   /ligand_id="ChEBI:CHEBI:37565"
FT   BINDING         118..120
FT                   /ligand="GTP"
FT                   /ligand_id="ChEBI:CHEBI:37565"
FT   BINDING         217..218
FT                   /ligand="GTP"
FT                   /ligand_id="ChEBI:CHEBI:37565"
FT   BINDING         276..279
FT                   /ligand="GTP"
FT                   /ligand_id="ChEBI:CHEBI:37565"
FT   MOD_RES         10
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8BH66"
FT   MOD_RES         22
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8BH66"
FT   MOD_RES         23
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8BH66"
FT   MOD_RES         395
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q6DD88"
FT   VAR_SEQ         518..522
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:17974005"
FT                   /id="VSP_044864"
FT   VARIANT         43
FT                   /note="D -> E (in dbSNP:rs17850684)"
FT                   /evidence="ECO:0000269|PubMed:15489334"
FT                   /id="VAR_058963"
FT   VARIANT         66
FT                   /note="E -> Q (in HSN1D; shows no significant changes in
FT                   GTPase activity and no changes in endoplasmic reticulum
FT                   morphology; dbSNP:rs200314808)"
FT                   /evidence="ECO:0000269|PubMed:21194679"
FT                   /id="VAR_065508"
FT   VARIANT         118
FT                   /note="R -> Q (in SPG3; dbSNP:rs606231265)"
FT                   /evidence="ECO:0000269|PubMed:24473461"
FT                   /id="VAR_071874"
FT   VARIANT         154
FT                   /note="Q -> E (in SPG3)"
FT                   /evidence="ECO:0000269|PubMed:20932283"
FT                   /id="VAR_067655"
FT   VARIANT         157
FT                   /note="L -> W (in SPG3; dbSNP:rs119476051)"
FT                   /evidence="ECO:0000269|PubMed:16533974"
FT                   /id="VAR_065509"
FT   VARIANT         161
FT                   /note="A -> P (in SPG3; affects endoplasmic reticulum and
FT                   Golgi morphology)"
FT                   /evidence="ECO:0000269|PubMed:14695538,
FT                   ECO:0000269|PubMed:17321752"
FT                   /id="VAR_019446"
FT   VARIANT         193
FT                   /note="F -> C (in dbSNP:rs17850683)"
FT                   /evidence="ECO:0000269|PubMed:15489334"
FT                   /id="VAR_058964"
FT   VARIANT         196
FT                   /note="Y -> C (in a patient with hereditary spastic
FT                   paraplegia; unknown pathological significance; no effect on
FT                   homodimerization and GTPase activity; dbSNP:rs1555364246)"
FT                   /evidence="ECO:0000269|PubMed:20718791,
FT                   ECO:0000269|PubMed:21220294"
FT                   /id="VAR_067656"
FT   VARIANT         217
FT                   /note="R -> Q (in SPG3; abolishes homodimerization and
FT                   GTPase activity and alters endoplasmic reticulum
FT                   morphology; dbSNP:rs119476049)"
FT                   /evidence="ECO:0000269|PubMed:12112092,
FT                   ECO:0000269|PubMed:18270207, ECO:0000269|PubMed:21220294,
FT                   ECO:0000269|PubMed:27619977"
FT                   /id="VAR_017146"
FT   VARIANT         239
FT                   /note="R -> C (in SPG3; affects endoplasmic reticulum and
FT                   Golgi morphology; dbSNP:rs119476046)"
FT                   /evidence="ECO:0000269|PubMed:11685207,
FT                   ECO:0000269|PubMed:17321752, ECO:0000269|PubMed:20718791,
FT                   ECO:0000269|PubMed:20932283"
FT                   /id="VAR_017147"
FT   VARIANT         247
FT                   /note="H -> P (in SPG3)"
FT                   /evidence="ECO:0000269|PubMed:14695538"
FT                   /id="VAR_019447"
FT   VARIANT         253
FT                   /note="V -> I (in SPG3; dbSNP:rs864622520)"
FT                   /evidence="ECO:0000269|PubMed:20718791,
FT                   ECO:0000269|PubMed:20932283, ECO:0000269|PubMed:24604904"
FT                   /id="VAR_067657"
FT   VARIANT         258
FT                   /note="H -> R (in SPG3; dbSNP:rs119476048)"
FT                   /evidence="ECO:0000269|PubMed:11685207"
FT                   /id="VAR_017148"
FT   VARIANT         259
FT                   /note="S -> Y (in SPG3; dbSNP:rs119476047)"
FT                   /evidence="ECO:0000269|PubMed:11685207"
FT                   /id="VAR_017149"
FT   VARIANT         355
FT                   /note="N -> K (in HSN1D; the mutant protein has decreased
FT                   GTPase activity compared to wild-type and causes disruption
FT                   of endoplasmic reticulum network morphology;
FT                   dbSNP:rs1555365597)"
FT                   /evidence="ECO:0000269|PubMed:21194679"
FT                   /id="VAR_065510"
FT   VARIANT         408
FT                   /note="M -> V (in SPG3; dbSNP:rs28939094)"
FT                   /evidence="ECO:0000269|PubMed:12939451"
FT                   /id="VAR_065511"
FT   VARIANT         413
FT                   /note="F -> V (in SPG3)"
FT                   /evidence="ECO:0000269|PubMed:20932283"
FT                   /id="VAR_067658"
FT   VARIANT         415
FT                   /note="R -> Q (in SPG3; dbSNP:rs397514712)"
FT                   /evidence="ECO:0000269|PubMed:23483706"
FT                   /id="VAR_071708"
FT   VARIANT         415
FT                   /note="R -> W (in SPG3; dbSNP:rs119476050)"
FT                   /evidence="ECO:0000269|PubMed:15184642,
FT                   ECO:0000269|PubMed:20932283, ECO:0000269|PubMed:23483706"
FT                   /id="VAR_065512"
FT   VARIANT         416
FT                   /note="R -> C (in SPG3; dbSNP:rs387906941)"
FT                   /evidence="ECO:0000269|PubMed:21336785"
FT                   /id="VAR_071709"
FT   VARIANT         436
FT                   /note="Missing (in SPG3; does not affect GTPase activity;
FT                   does not affect interaction with SPAST; patients'
FT                   lymphoblasts show decreased protein levels but normal
FT                   levels of mRNA; dbSNP:rs1595625206)"
FT                   /evidence="ECO:0000269|PubMed:17427918"
FT                   /id="VAR_065513"
FT   VARIANT         440
FT                   /note="N -> T (in SPG3)"
FT                   /evidence="ECO:0000269|PubMed:20932283"
FT                   /id="VAR_067659"
FT   VARIANT         495
FT                   /note="R -> W (in SPG3; affects endoplasmic reticulum and
FT                   Golgi morphology; dbSNP:rs864622269)"
FT                   /evidence="ECO:0000269|PubMed:17321752,
FT                   ECO:0000269|PubMed:20718791, ECO:0000269|PubMed:20932283"
FT                   /id="VAR_067660"
FT   MUTAGEN         77
FT                   /note="R->A: Abolishes GTPase activity and impairs
FT                   homodimerization."
FT                   /evidence="ECO:0000269|PubMed:21220294,
FT                   ECO:0000269|PubMed:23334294"
FT   MUTAGEN         77
FT                   /note="R->E: Abolishes homodimerization."
FT                   /evidence="ECO:0000269|PubMed:21220294,
FT                   ECO:0000269|PubMed:23334294"
FT   MUTAGEN         80
FT                   /note="K->A: Alters endoplasmic reticulum morphogenesis."
FT                   /evidence="ECO:0000269|PubMed:18270207,
FT                   ECO:0000269|PubMed:27619977"
FT   MUTAGEN         151
FT                   /note="F->S: Affects endoplasmic reticulum and Golgi
FT                   morphology."
FT                   /evidence="ECO:0000269|PubMed:17321752"
FT   MUTAGEN         162
FT                   /note="T->P: Affects endoplasmic reticulum and Golgi
FT                   morphology."
FT                   /evidence="ECO:0000269|PubMed:17321752"
FT   MUTAGEN         191
FT                   /note="Q->R: Abolishes homodimerization."
FT                   /evidence="ECO:0000269|PubMed:21220294"
FT   MUTAGEN         247
FT                   /note="H->R: Impairs homodimerization and GTPase activity."
FT                   /evidence="ECO:0000269|PubMed:21220294"
FT   MUTAGEN         398
FT                   /note="S->Y: Affects endoplasmic reticulum and Golgi
FT                   morphology."
FT                   /evidence="ECO:0000269|PubMed:17321752"
FT   STRAND          19..21
FT                   /evidence="ECO:0007829|PDB:6XJN"
FT   STRAND          23..30
FT                   /evidence="ECO:0007829|PDB:6XJN"
FT   STRAND          34..40
FT                   /evidence="ECO:0007829|PDB:6B9F"
FT   TURN            42..44
FT                   /evidence="ECO:0007829|PDB:3QOF"
FT   STRAND          46..48
FT                   /evidence="ECO:0007829|PDB:6B9F"
FT   HELIX           50..57
FT                   /evidence="ECO:0007829|PDB:6B9F"
FT   TURN            60..64
FT                   /evidence="ECO:0007829|PDB:6B9F"
FT   STRAND          65..79
FT                   /evidence="ECO:0007829|PDB:6B9F"
FT   HELIX           80..92
FT                   /evidence="ECO:0007829|PDB:6B9F"
FT   TURN            93..95
FT                   /evidence="ECO:0007829|PDB:6B9D"
FT   TURN            97..100
FT                   /evidence="ECO:0007829|PDB:6B9F"
FT   STRAND          115..117
FT                   /evidence="ECO:0007829|PDB:6B9F"
FT   STRAND          122..128
FT                   /evidence="ECO:0007829|PDB:6B9F"
FT   STRAND          130..133
FT                   /evidence="ECO:0007829|PDB:6B9F"
FT   STRAND          135..137
FT                   /evidence="ECO:0007829|PDB:3Q5D"
FT   STRAND          139..147
FT                   /evidence="ECO:0007829|PDB:6B9F"
FT   STRAND          153..156
FT                   /evidence="ECO:0007829|PDB:6XJN"
FT   HELIX           157..170
FT                   /evidence="ECO:0007829|PDB:6B9F"
FT   STRAND          172..181
FT                   /evidence="ECO:0007829|PDB:6B9F"
FT   HELIX           184..199
FT                   /evidence="ECO:0007829|PDB:6B9F"
FT   STRAND          208..217
FT                   /evidence="ECO:0007829|PDB:6B9F"
FT   TURN            222..224
FT                   /evidence="ECO:0007829|PDB:6B9F"
FT   HELIX           229..240
FT                   /evidence="ECO:0007829|PDB:6B9F"
FT   TURN            244..246
FT                   /evidence="ECO:0007829|PDB:6XJN"
FT   HELIX           248..260
FT                   /evidence="ECO:0007829|PDB:6B9F"
FT   STRAND          261..268
FT                   /evidence="ECO:0007829|PDB:6B9F"
FT   HELIX           274..278
FT                   /evidence="ECO:0007829|PDB:6B9F"
FT   STRAND          279..281
FT                   /evidence="ECO:0007829|PDB:6B9G"
FT   HELIX           286..288
FT                   /evidence="ECO:0007829|PDB:6B9F"
FT   HELIX           291..305
FT                   /evidence="ECO:0007829|PDB:6B9F"
FT   TURN            307..309
FT                   /evidence="ECO:0007829|PDB:6B9F"
FT   HELIX           322..337
FT                   /evidence="ECO:0007829|PDB:6B9F"
FT   STRAND          338..341
FT                   /evidence="ECO:0007829|PDB:6B9F"
FT   HELIX           347..375
FT                   /evidence="ECO:0007829|PDB:6B9F"
FT   STRAND          377..380
FT                   /evidence="ECO:0007829|PDB:3Q5D"
FT   HELIX           384..404
FT                   /evidence="ECO:0007829|PDB:6B9F"
FT   HELIX           410..437
FT                   /evidence="ECO:0007829|PDB:6B9F"
FT   HELIX           443..446
FT                   /evidence="ECO:0007829|PDB:6B9F"
SQ   SEQUENCE   558 AA;  63544 MW;  68A33C39DD43504C CRC64;
     MAKNRRDRNS WGGFSEKTYE WSSEEEEPVK KAGPVQVLIV KDDHSFELDE TALNRILLSE
     AVRDKEVVAV SVAGAFRKGK SFLMDFMLRY MYNQESVDWV GDYNEPLTGF SWRGGSERET
     TGIQIWSEIF LINKPDGKKV AVLLMDTQGT FDSQSTLRDS ATVFALSTMI SSIQVYNLSQ
     NVQEDDLQHL QLFTEYGRLA MEETFLKPFQ SLIFLVRDWS FPYEFSYGAD GGAKFLEKRL
     KVSGNQHEEL QNVRKHIHSC FTNISCFLLP HPGLKVATNP NFDGKLKEID DEFIKNLKIL
     IPWLLSPESL DIKEINGNKI TCRGLVEYFK AYIKIYQGEE LPHPKSMLQA TAEANNLAAV
     ATAKDTYNKK MEEICGGDKP FLAPNDLQTK HLQLKEESVK LFRGVKKMGG EEFSRRYLQQ
     LESEIDELYI QYIKHNDSKN IFHAARTPAT LFVVIFITYV IAGVTGFIGL DIIASLCNMI
     MGLTLITLCT WAYIRYSGEY RELGAVIDQV AAALWDQGST NEALYKLYSA AATHRHLYHQ
     AFPTPKSEST EQSEKKKM
//
